前收市價 | 39.88 |
開市 | 40.39 |
買盤 | 40.35 x 0 |
賣出價 | 40.58 x 0 |
今日波幅 | 40.39 - 40.39 |
52 週波幅 | 35.22 - 71.44 |
成交量 | |
平均成交量 | 6 |
市值 | 無 |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | 無 |
業績公佈日 | 2024年5月15日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.
Eisai just reached the finish line with its long-fought battle to gain Medicare approval for Alzheimer's drug Leqembi. But the company says more work remains.
Biogen and Eisai's second attempt at a new class of Alzheimer's treatments faces pressure despite regulatory and CMS greenlight.